PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2014.1262014474790-795Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal CancerSeung Tae Kim, Tae Won Kim, Kyu-pyo Kim, Tae-You Kim, Sae-Won Han, Ji Yun Lee, Sung Hee Lim, Min-Young Lee, Haesu Kim, Young Suk Parkhttp://e-crt.org/upload/pdf/crt-2014-126.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2014.126, http://www.e-crt.org/upload/pdf/crt-2014-126.pdf
ESMO Open10.1136/esmoopen-2017-000205201723e000205Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancerGerald Prager, Guillem Argiléshttps://api.elsevier.com/content/article/PII:S2059702920324212?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S2059702920324212?httpAccept=text/plain, https://syndication.highwire.org/content/doi/10.1136/esmoopen-2017-000205
Annals of Oncology10.1093/annonc/mdw199.153201627ii47P-159 Regorafenib vs TAS-102 as salvage-line treatment in patients with metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison studyM. Kotaka, H. Satake, Y. Okita, Y. Hatachi, T. Kotake, H. Hashida, T. Kato, A. Tsujihttps://api.elsevier.com/content/article/PII:S0923753419456536?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419456536?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/27/suppl_2/ii47/7508583/mdw199.153.pdf
Clinical Colorectal Cancer10.1016/j.clcc.2018.02.0092018172e381-e383Regorafenib or Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer? A Perspective on the Basis of Pharmacological CostsJacopo Giuliani, Andrea Bonettihttps://api.elsevier.com/content/article/PII:S1533002817302785?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1533002817302785?httpAccept=text/plain
Annals of Oncology10.1093/annonc/mdx659.010201728x45Palliative treatment of refractory metastatic colorectal cancer using regorafenib: Macau experienceX. Peng, Y. Lin, Y. Wang, C. Hui, C. Lamhttps://api.elsevier.com/content/article/PII:S0923753419561245?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419561245?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/28/suppl_10/mdx659.010/21936338/mdx659.010.pdf
Annals of Oncology10.1093/annonc/mdy151.232201829v65Trifluridine/tipiracil vs regorafenib as salvage-line treatment in patients with metastatic colorectal cancer: A multicenter retrospective studyM. Kotaka, M. Ogata, T. Ogata, Y. Hatachi, H. Yasui, T. Kato, A. Tsuji, H. Satakehttps://api.elsevier.com/content/article/PII:S0923753419339699?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419339699?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/29/suppl_5/mdy151.232/25057234/mdy151.232.pdf
Clinical Colorectal Cancer10.1016/j.clcc.2018.08.0032018174e751-e761Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United StatesSang Kyu Cho, Joel W. Hay, Afsaneh Barzihttps://api.elsevier.com/content/article/PII:S1533002818301671?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1533002818301671?httpAccept=text/plain
Clinical Colorectal Cancer10.1016/j.clcc.2021.12.0032022212132-140Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective “Real-World Study”Clélia Coutzac, Isabelle Trouilloud, Pascal Artru, Julie Henriques, Thérese Masson, Solene Doat, Olivier Bouché, Romain Coriat, Angélique Saint, Valérie Moulin, Dewi Vernerey, Claire Gallois, Christelle De La Fouchardière, David Tougeron, Julien Taiebhttps://api.elsevier.com/content/article/PII:S1533002821001444?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1533002821001444?httpAccept=text/plain
Pharmacy Today10.1016/s1042-0991(15)31629-72012181140Regorafenib: Novel treatment for refractory colorectal cancerMaria G. Tanzihttps://api.elsevier.com/content/article/PII:S1042099115316297?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1042099115316297?httpAccept=text/plain
Current Colorectal Cancer Reports10.1007/s11888-017-0381-62017134325-333Treatment of Refractory Colorectal Cancer: Regorafenib vs. TAS-102Jae Ho Jeong, Yong Sang Hong, Tae Won Kimhttp://link.springer.com/article/10.1007/s11888-017-0381-6/fulltext.html, http://link.springer.com/content/pdf/10.1007/s11888-017-0381-6.pdf, http://link.springer.com/content/pdf/10.1007/s11888-017-0381-6.pdf